Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China.
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
J Med Virol. 2020 Oct;92(10):2067-2073. doi: 10.1002/jmv.25972. Epub 2020 Jun 2.
This retrospective study aimed to analysis clinical characteristics and outcomes of cancer patients with novel coronavirus disease-19 (COVID-19). Medical records, laboratory results and radiologic findings of 52 cancer patients with COVID-19 were collected, clinical characteristics and outcomes were summarized. A total of 52 cancer patients with COVID-19 were included. Median age of 52 cancer patients with COVID-19 was 63 years (34-98). Thirty-three (63.5%) patients were mild and 19 (36.5%) were severe/critical. Lung cancer was the most frequent cancer type (10, 19.2%). The common symptoms were as follows: fever (25%), dry cough (17.3%), chest distress (11.5%), and fatigue (9.6%). There were 33 (63.5%) patients had comorbidities, the most common symptom was hypertension (17, 51.5%). Twenty-six (78.8%) patients developed pneumonia on admission. Lymphocytes (0.6 × 109/L) decreased in both mild and severe/critical patients. Median levels of D-dimer, C-reactive protein, procalcitonin, and lactate dehydrogenase were 2.8 mg/L, 70.5 mg/L, 0.3 ng/mL, and 318 U/L, respectively, which increased significantly in severe/critical patients compared with the mild patients. Interleukin-6 (12.6 pg/mL) increased in both mild and severe/critical patients, there was a significant difference between them. Complications were observed in 29 (55.8%) patients, such as liver injury (19, 36.5%), acute respiratory distress syndrome (9, 17.3%), sepsis (8, 15.4%), myocardial injury (8, 15.4%), renal insufficiency (4, 7.7%), and multiple organ dysfunction syndrome (3, 5.8%). Eleven (21.2%) patients with cancer died. The infection rate of severe acute respiratory syndrome coronavirus 2 in patients with cancer was higher than the general population, cancer patients with COVID-19 showed deteriorating conditions and poor outcomes.
本回顾性研究旨在分析新型冠状病毒病-19（COVID-19）合并癌症患者的临床特征和结局。收集了 52 例 COVID-19 合并癌症患者的病历、实验室结果和影像学资料，总结了其临床特征和结局。共纳入 52 例 COVID-19 合并癌症患者，中位年龄 63 岁（34-98 岁）。33 例（63.5%）为轻症，19 例（36.5%）为重症/危重症。肺癌是最常见的癌症类型（10 例，19.2%）。常见症状为发热（25%）、干咳（17.3%）、胸闷（11.5%）和乏力（9.6%）。33 例（63.5%）患者合并基础疾病，最常见的症状为高血压（17 例，51.5%）。入院时 26 例（78.8%）患者已发生肺炎。淋巴细胞（0.6×109/L）在轻症和重症/危重症患者中均减少。D-二聚体、C 反应蛋白、降钙素原和乳酸脱氢酶的中位水平分别为 2.8mg/L、70.5mg/L、0.3ng/mL 和 318U/L，重症/危重症患者明显高于轻症患者。白细胞介素-6（12.6pg/mL）在轻症和重症/危重症患者中均升高，两者间差异有统计学意义。29 例（55.8%）患者出现并发症，包括肝功能损伤（19 例，36.5%）、急性呼吸窘迫综合征（9 例，17.3%）、脓毒症（8 例，15.4%）、心肌损伤（8 例，15.4%）、肾功能不全（4 例，7.7%）和多器官功能障碍综合征（3 例，5.8%）。11 例（21.2%）癌症患者死亡。癌症患者严重急性呼吸综合征冠状病毒 2 的感染率高于一般人群，COVID-19 合并癌症患者病情恶化，结局不良。
